Mirabegron displays anticancer effects by globally browning adipose tissues

Area of Science:

• Oncology
• Metabolic research
• Pharmacology

Background:

• Cancer cells exhibit metabolic reprogramming, relying on glycolysis for growth and metastasis.
• The role of adipose metabolism in tumor progression and therapeutic targeting remains underexplored.
• Targeting metabolic pathways presents a promising avenue for novel cancer therapies.

Purpose of the Study:

• To investigate the potential of targeting adipose metabolism for cancer treatment.
• To evaluate the anticancer efficacy of mirabegron, a drug for overactive bladder.
• To elucidate the mechanism of action of mirabegron in cancer therapy.

Main Methods:

• Utilized various animal cancer models to test mirabegron's efficacy.
• Investigated the role of adipose tissue browning in mediating anticancer effects.
• Examined the impact of genetic deletion of uncoupling protein 1 (UCP1) and removal of brown adipose tissue.

Main Results:

• Mirabegron demonstrated significant anticancer effects across diverse cancer models, including pancreatic and liver cancers.
• The drug's efficacy was directly linked to the browning of adipose tissues.
• Genetic ablation of UCP1 or removal of brown adipose tissue abolished mirabegron's anticancer activity.

Conclusions:

• Mirabegron represents a novel class of anticancer drugs with a unique mechanism of action.
• Targeting adipose tissue browning offers a new therapeutic strategy for multiple cancer types.
• Mirabegron's repurposing holds potential for treating intractable cancers.